Immunic Inc (IMUX) Stock Price, Quote & News

Company Profile

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restor...

Industry: Biotechnology

Sector: Healthcare

Phone: 332 255 9818

Website: imux.com

Address:

1200 Avenue of the Americas, Suite 200, New York, United States

mplaster Oct. 24 at 7:04 PM

$IMUX why dominget the feeling this is going to.rocket.any day

1 · Reply

Tonsauce123 Oct. 24 at 6:17 PM

$IMUX where my retardio’s at?

2 · Reply

Jw242 Oct. 24 at 1:49 PM

$IMUX bring on the red.

0 · Reply

Jw242 Oct. 24 at 12:23 PM

$IMUX good stat here….we have been green pre market 41 of the last 43 trading days Red at days end 36 of the last 43 Smoke and mirrors I guess but why buy 40k shares at $.79 this morning if you know $.76 or $.77 is coming?

1 · Reply

Cattitude Oct. 23 at 11:32 PM

$IMUX dump dump dump that’s all it ever was and all it’ll ever be. Main key is partnership or bo. Warrants fuck us all day everyday. This would’ve been a dream to keep flipping a ago, but all is been lately is a downfall day after day 😡

0 · Reply

Tradergrows Oct. 23 at 8:50 PM

$IMUX Pure speculation here but what if they're under NDA? No mention of financing, delisting, partnerships, or FDA approval. Nada. Just updates on the science and looking forward to Phase 3. The silence is interesting. Maybe Vitt and Tardio are cooking in the kitchen?

1 · Reply

ErnieWorthing84 Oct. 23 at 7:45 PM

$IMUX Strong talking points at HC Wain today. This thing is going to be a cash cow on approval. Daily oral for life

1 · Reply

Starflash Oct. 23 at 3:17 PM

$IMUX These up and downs mean nothing. Swing it or let it be. The interesting part comes 2026.

1 · Reply

Jw242 Oct. 23 at 2:11 PM

$IMUX sucks. But this is the life lesson I e signed up for Thanks prez Tardio

1 · Reply

rizmanasjr Oct. 23 at 12:03 PM

$IMUX 🤷‍♂️ https://x.com/ImmunicInc/status/1981329765790335475

2 · Reply

Immunic to Participate in Scientific and Investor Conferences in October

Sep 25, 2025, 6:30 AM EDT - 4 weeks ago

Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis

Sep 9, 2025, 6:30 AM EDT - 6 weeks ago

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis

Sep 4, 2025, 6:30 AM EDT - 7 weeks ago

Immunic to Participate in Investor and Scientific Conferences in September

Aug 7, 2025, 6:30 AM EDT - 2 months ago

Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jun 24, 2025, 6:30 AM EDT - 4 months ago

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

Jun 9, 2025, 5:51 PM EDT - 4 months ago

Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted

Jun 5, 2025, 6:30 AM EDT - 5 months ago

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS

Jun 3, 2025, 4:01 PM EDT - 5 months ago

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering

Jun 2, 2025, 6:30 AM EDT - 5 months ago

Immunic to Participate in Investor, Scientific and Industry Conferences in June

May 29, 2025, 7:05 AM EDT - 5 months ago

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering

May 28, 2025, 4:02 PM EDT - 5 months ago

Immunic, Inc. Announces Proposed Public Offering

May 2, 2025, 6:30 AM EDT - 6 months ago

Immunic to Participate in Scientific and Industry Conferences in May

Apr 30, 2025, 7:30 AM EDT - 6 months ago

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial

Apr 28, 2025, 2:09 AM EDT - 6 months ago

Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher

Apr 10, 2025, 1:00 PM EDT - 7 months ago

Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Apr 9, 2025, 8:10 AM EDT - 7 months ago

Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Apr 1, 2025, 6:30 AM EDT - 7 months ago

Immunic, Inc. to Participate in Scientific and Industry Conferences in April

Mar 3, 2025, 6:30 AM EST - 8 months ago

Immunic to Participate in Scientific and Investor Conferences in March

Feb 26, 2025, 6:30 AM EST - 8 months ago

Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis

Feb 20, 2025, 7:30 AM EST - 8 months ago

Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing

Feb 4, 2025, 6:30 AM EST - 9 months ago

Immunic to Participate in Investor and Scientific Conferences in February

Jan 7, 2025, 6:30 AM EST - 10 months ago

Immunic Highlights 2024 Accomplishments and Upcoming Milestones

Nov 26, 2024, 6:30 AM EST - 11 months ago

Immunic, Inc. to Participate in Investor Conference in December

Nov 13, 2024, 6:30 AM EST - 1 year ago

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology

Nov 9, 2024, 8:37 AM EST - 1 year ago

Immunic, Inc. (IMUX) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 6:30 AM EST - 1 year ago

Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 31, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

Oct 29, 2024, 6:30 AM EDT - 1 year ago

Immunic to Participate in Industry, Scientific and Investor Conferences in November

Oct 22, 2024, 6:30 AM EDT - 1 year ago

Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis

Sep 18, 2024, 6:30 AM EDT - 1 year ago

Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis

Sep 4, 2024, 6:30 AM EDT - 1 year ago

Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome

Aug 28, 2024, 6:30 AM EDT - 1 year ago

Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September

Aug 9, 2024, 6:55 PM EDT - 1 year ago

Immunic, Inc. (IMUX) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 1, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update

Jul 24, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec

Jul 9, 2024, 6:30 AM EDT - 1 year ago

Immunic Appoints Jason Tardio as Chief Operating Officer and President

May 28, 2024, 6:30 AM EDT - 1 year ago

Immunic to Participate in Industry and Scientific Conferences in June

May 8, 2024, 2:20 PM EDT - 1 year ago

Immunic, Inc. (IMUX) Q1 2024 Earnings Call Transcript

May 8, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 6, 2024, 6:30 AM EDT - 1 year ago

Immunic to Participate in Investor and Scientific Conferences in May

May 1, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update

Apr 30, 2024, 6:30 AM EDT - 1 year ago

Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation

Apr 4, 2024, 6:30 AM EDT - 1 year ago

Immunic to Host MS R&D Day and Participate in Investor Conferences in April

Mar 20, 2024, 6:30 AM EDT - 1 year ago

Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States

Mar 7, 2024, 6:30 AM EST - 1 year ago

Immunic to Participate in Investor and Scientific Conferences in March

Feb 29, 2024, 6:30 AM EST - 1 year ago

Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024

Feb 22, 2024, 3:38 PM EST - 1 year ago

Immunic, Inc. (IMUX) Q4 2023 Earnings Call Transcript

Feb 22, 2024, 6:30 AM EST - 1 year ago

Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update

mplaster Oct. 24 at 7:04 PM

$IMUX why dominget the feeling this is going to.rocket.any day

1 · Reply

Tonsauce123 Oct. 24 at 6:17 PM

$IMUX where my retardio’s at?

2 · Reply

Jw242 Oct. 24 at 1:49 PM

$IMUX bring on the red.

0 · Reply

Jw242 Oct. 24 at 12:23 PM

1 · Reply

Cattitude Oct. 23 at 11:32 PM

0 · Reply

Tradergrows Oct. 23 at 8:50 PM

1 · Reply

ErnieWorthing84 Oct. 23 at 7:45 PM

$IMUX Strong talking points at HC Wain today. This thing is going to be a cash cow on approval. Daily oral for life

1 · Reply

Starflash Oct. 23 at 3:17 PM

$IMUX These up and downs mean nothing. Swing it or let it be. The interesting part comes 2026.

1 · Reply

Jw242 Oct. 23 at 2:11 PM

$IMUX sucks. But this is the life lesson I e signed up for Thanks prez Tardio

1 · Reply

rizmanasjr Oct. 23 at 12:03 PM

$IMUX 🤷‍♂️ https://x.com/ImmunicInc/status/1981329765790335475

2 · Reply

Johnnyb1973 Oct. 23 at 9:49 AM

$IMUX It ain't about how hard you hit. It's about how hard you can get hit and keep moving forward. How much you can take and keep moving forward. That's how winning is done!

0 · Reply

Cattitude Oct. 22 at 8:16 PM

$IMUX this is getting harder and harder to stomach 😿

1 · Reply

Whyasking Oct. 22 at 5:27 PM

$IMUX only one thing is necessary. partnership or bo. if they are participating on investor conferences it is a sign there is no partner candidate. we will see 0,3x $ in near future

0 · Reply

Jw242 Oct. 22 at 1:57 PM

$IMUX market likes fake meat more than vido at the moment 🤦‍♂️

1 · Reply

takingstock73 Oct. 21 at 2:17 PM

$IMUX RS doubtful, more likely dropping some big news or a strong partnership. That's incoming soon

1 · Reply

Sicilian1 Oct. 21 at 1:47 PM

$IMUX REVERSE SPLIT COMING SOON?

1 · Reply

takingstock73 Oct. 21 at 1:03 PM

$IMUX let's start creeping

1 · Reply

hkkim953 Oct. 20 at 11:18 PM

$IMUX why extreme bearish? No one is buying this stock?

0 · Reply

Cattitude Oct. 20 at 8:25 PM

$IMUX

0 · Reply

ChompNation Oct. 20 at 8:15 PM

$IMUX Great price to buy!

0 · Reply

Jw242 Oct. 20 at 5:09 PM

$IMUX warrants warrants and more warrants

0 · Reply

Tonsauce123 Oct. 20 at 12:42 PM

$IMUX i wanna get in on this but the short term seems dead. Only catalyst to look for is 2026 phase 3 news

0 · Reply

Market Cap	76.94M
Revenue (ttm)	0.00
Net Income (ttm)	-100.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,202,100
Avg Vol	1,447,508
Day's Range	N/A - N/A
Shares Out	98.65M
Stochastic %K	6%
Beta	1.56
Analysts	Strong Sell
Price Target	$6.35